Investor Presentation - AngelMed Guardian FDA Approval
Filed with ASX · · 6 pages · English
Hydrix Limited (ASX: HYD) attaches an investor presentation in relation to the recent FDA approval of the AngelMed Guardian device, as announced to the market on 28 June 2021. A recorded presentation given by Executive Chairman Gavin Coote, which provides a narrative to the Investor Presentation slides, can be accessed at the following link: Video link -ENDS- Authorisation: This announcement has b
In the deck
Story so far
Earlier from Hydrix
- AngelMed receives FDA approval for Guardian upgraded battery
- 2020 AGM - Executive Chairmans Presentation
- First in human trials of Phyzhon Health PHYRARI FFR-WIRE
- Phyzhon appoints Hydrix as exclusive distributor
- Hydrix raises $10m under institutional placement
Later from Hydrix
- Hydrix completes TGA submission for AngelMed Guardian System
- AngelMed completes its first USA commercial Guardian implant
- Commercial arrangement between Hydrix and Memphasys
- FY2021 Letter from Executive Chairman
- FY2021 Appendix 4E and Financial Report
Follow Hydrix into a list and get an email when it puts out news.
Follow Hydrix